Cellectis’ Miraculous Saving of a Baby Girl. What’s the impact on the CAR-T field?

06/11/2015 - 2 minutes

About 30%. That’s how Cellectis‘ NASDAQ stock price has jumped between the 4th and the 5th of November. But why? Basically, because of the first human success of their allogeneic CAR-T therapy!

Picture1The Great Ormond Street Hospital (UK) treated a young patient with refractory relapsed Acute Lymphoblastic Leukemia (ALL) with Cellectis’ allogeneic UCART19 product candidate in June. To put this plainly, the CAR-T therapy was her last chance…and miraculously, after only two months she seems to be cured!

This is a huge deal for many patients around the world who could benefit from such therapies in the future. Competitors approaches include autologous CAR-T therapy which worth several hundreds thousand dollars per treatment, and therefore limit the number of patients which can access those therapies.

Cellectis’ allogeneic CAR-T therapy can be manufactured as one batch for several patient (allogeneic means that we extract T cells from a health patient as opposed to autologous which is from the patient). That will therefore drastically reduce the cost of the therapy.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!